Luczyński Włodzimierz, Stasiak-Barmuta Anna, Iłendo Elzbieta, Krawczuk-Rybak Maryna, Malinowska Iwona, Mitura-Lesiuk Małgorzata, Parfieńczyk Adam, Szymański Marcin
Department of Pediatric Oncology, Medical University of Białystok, Poland.
Acta Biochim Pol. 2006;53(2):377-82. Epub 2006 May 29.
Despite the very high percentage of long-term remissions in acute lymphoblastic leukemia (ALL) in children, some of them suffer from recurrence of the disease. New treatment modalities, e.g. effective geno- and immunotherapy are needed. The use of neoplasmatic cells to present tumor antigens is one of the approaches in cancer vaccines. ALL cells lack the expression of costimulatory molecules and are poor antigen presenting cells (APCs) for T-cell activation. CD40/40L interaction stimulates B-cells to proliferate, differentiate, upregulate costimulatory molecules and increase antigen presentation. The aim of the study was to test the hypothesis that ALL cells can be turned into professional APCs by CD40L activation. Children with B-cell precursor ALL were enrolled into the study. Mononuclear cells from bone marrow or peripheral blood were stimulated with CD40L and interleukin 4.
尽管儿童急性淋巴细胞白血病(ALL)的长期缓解率非常高,但仍有一些患儿会出现疾病复发。因此需要新的治疗方式,例如有效的基因治疗和免疫治疗。利用肿瘤细胞呈递肿瘤抗原是癌症疫苗的方法之一。ALL细胞缺乏共刺激分子的表达,是较差的用于激活T细胞的抗原呈递细胞(APC)。CD40/40L相互作用可刺激B细胞增殖、分化、上调共刺激分子并增强抗原呈递。本研究的目的是验证ALL细胞可通过CD40L激活转变为专业APC这一假说。B细胞前体ALL患儿被纳入本研究。用CD40L和白细胞介素4刺激来自骨髓或外周血的单核细胞。
1)培养后,我们发现所有评估的共刺激、黏附和激活分子即CD1a、CD11c、CD40、CD54、CD80、CD83、CD86、CD123、HLA I类和II类分子均上调;2)CD40L激活的ALL细胞诱导同种异体T细胞增殖(通过[³H]胸苷掺入法测定)。这些结果证实了利用CD40L系统增强ALL细胞免疫原性的可能性,并表明该方法可用于免疫治疗试验。